More drugs originate outside the industry than it claims
BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1354 (Published 04 February 2014) Cite this as: BMJ 2014;348:g1354- Jacqui Young
- 1London
Many innovative drugs, especially to treat rare diseases, originate not from large drug companies but from small enterprises or academia, a new study has shown.
The research by the European Medicines Agency shows that 44% of innovative drugs recommended for marketing authorisation in the European Union originated from small or medium sized enterprises, academia, public bodies, and public-private partnerships.1
This seems to contradict the claim by Stephen Whitehead, chief executive of the Association of the British Pharmaceutical Industry, that the industry was responsible for developing 90% of the drugs available to patients. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.